Survival Rate and Prognosis for Stomach Cancer

• Stage at diagnosis makes a dramatic difference for stomach cancer: SEER figures put 5-year relative survival at 78.1% for tumors confined to the stomach, versus just 8.1% once the disease has reached distant organs.
• Combined across every stage, survival comes to 39.8% for people diagnosed with this disease in the United States — a figure pulled down by the fact that only about a third of cases are found while still localized.
• Beyond stage, tumor grade, where the tumor sits in the stomach, how deeply it has grown into the stomach wall, and whether it can be fully removed with surgery all shape an individual’s prognosis for stomach cancer.
• Newer targeted therapies and immunotherapy, guided by biomarker testing, have expanded treatment options for some patients with advanced or metastatic disease.
• Survival statistics are drawn from large groups of people tracked over time, so they cannot tell you exactly what will happen in an individual case.

Overall Stomach Cancer Survival Rates

When discussing stomach cancer survival rates, it helps to know what the numbers do and do not tell you. Doctors most often rely on a statistic called the 5-year relative survival rate — it compares how many people with stomach cancer remain alive five years after diagnosis against how many similarly aged, same-sex people without the disease remain alive over that same stretch of time. It is a population-level estimate, not a forecast for any single patient.

This page relies on population-based statistics from the SEER Program at the National Cancer Institute, using U.S. cases of stomach cancer diagnosed from 2016 through 2022. Combined across every stage, that survival figure comes to 39.8%. The number blends patients caught while the tumor was still confined to the stomach with those diagnosed after it had already spread, so it is strongly shaped by how early the disease is typically found: only about 32% of stomach cancers are picked up at the localized stage, which is one reason the all-stage average sits well below the localized-stage figure described below.

These survival statistics stomach cancer figures rely on large population studies and are updated periodically as newer data become available. Because it takes years to see the full effect of newer treatments, current survival numbers may not yet reflect the most recent advances in care. They are best used as a general starting point for a conversation with an oncology team, who can weigh a person’s specific diagnosis, overall health, and treatment plan.

Survival Rates by Stomach Cancer Stage

How far stomach cancer has grown or spread by the time it is found is the single strongest factor shaping the prognosis for stomach cancer. Staging is commonly simplified into three groups: localized, meaning the cancer is still confined to the stomach; regional, meaning it has reached nearby lymph nodes or tissue; and distant, meaning it has spread to organs elsewhere in the body, such as the liver, lungs, or peritoneum.

The gap between these numbers is large — five-year survival is roughly nine times higher for localized disease than for distant disease. Stomach cancer often causes few or no clear symptoms in its earliest stages, which is part of why most cases in this data were not caught while still localized; timely evaluation of persistent digestive symptoms gives the best chance of finding the cancer while more treatment options, including surgery aimed at removing the entire tumor, are still available.

Factors Influencing Stomach Cancer Prognosis

Beyond stage, several other factors influence the prognosis for stomach cancer. These help explain why two people diagnosed at a similar stage can still have different outlooks, and they help a care team tailor a treatment plan to the individual.

Tumor Characteristics and Location

• Type and Grade: Most stomach cancers are adenocarcinomas. The tumor’s grade — a lab assessment of how unusual the cancer cells appear compared with normal stomach tissue — can add some prognostic information, since higher-grade tumors tend to behave more aggressively.
• Location: Where the tumor sits within the stomach matters. The National Cancer Institute notes that even when caught at a localized stage, cancer near the top of the stomach, close to where it meets the esophagus (the cardia), tends to carry a lower five-year survival — roughly 10%–15% — than similarly localized cancer lower in the stomach, where more than half of patients can be cured.
• Genetic Markers: Some stomach cancers carry biomarkers such as HER2 protein overexpression or specific PD-L1 levels. Testing for these does not change the stage-based outlook on its own, but it can identify patients who may be eligible for targeted therapy or immunotherapy, particularly once the disease has spread outside the stomach.
• Depth of Invasion: How far the tumor has grown into or through the layers of the stomach wall, together with whether nearby lymph nodes are involved, is a core part of staging and is closely tied to prognosis.

Patient Health and Treatment Response

• Overall Health and Age: A patient’s general health, including other medical conditions and age, can affect how well they tolerate surgery and other intensive treatments, which in turn can influence outcomes.
• Nutritional Status: Weight loss and difficulty eating are common with stomach cancer, especially when a tumor partly blocks the stomach. Maintaining nutrition before, during, and after treatment is an important part of supportive care and can help patients tolerate therapy.
• Response to Treatment: How strongly a tumor responds to initial therapy — chemotherapy, radiation, or targeted treatment — offers a meaningful clue about prognosis; patients whose cancer responds well tend to have better long-term outcomes.
• Surgical Resectability: Whether a surgeon can remove all visible cancer with no cancer cells left at the cut edges of tissue — a complete, or margin-free, resection — is one of the strongest prognostic factors, especially for localized and regional disease.

Advancements in Treatment and Outlook

Treatment for stomach cancer continues to evolve. Removing part or the entire stomach through surgery (gastrectomy) remains the main option when the tumor can be fully taken out; chemotherapy is often paired with it, either beforehand to make the tumor smaller before the operation or afterward to lower the chance the cancer comes back. In select cases of very early, superficial cancer, endoscopic procedures can remove the tumor from the lining of the stomach without full surgery.

For cancer that has spread beyond the stomach, targeted therapy and immunotherapy have broadened the options beyond chemotherapy alone. Drugs aimed at HER2-positive tumors, such as trastuzumab, and immune checkpoint inhibitors such as nivolumab and pembrolizumab are now used for some patients with advanced or metastatic disease, guided by biomarker testing of the tumor. These options do not apply to everyone — eligibility depends on the specific biomarkers a tumor carries — but for those who qualify, they add choices beyond earlier chemotherapy-only regimens.

Even so, population data show that stomach cancer diagnosed at an advanced stage, while treatable, is rarely curable — which is why the stage at diagnosis remains the dominant factor in prognosis. Continued research into surgical technique, drug combinations, and biomarker-guided treatment is aimed at extending survival further, particularly for patients whose cancer has spread.

Frequently Asked Questions

Here are answers to some common questions regarding stomach cancer survival and prognosis.

What is the average stomach cancer survival rate?

The average 5-year relative survival rate across all stages of stomach cancer is 39.8% in the United States, based on SEER data. This is an overall statistic; survival is much higher, around 78%, for cancer found while still confined to the stomach, and much lower, around 8%, once it has spread to distant organs. A doctor familiar with a person’s specific diagnosis and stage can put these numbers in context.

How does the stage of cancer affect the prognosis for stomach cancer?

Stage is the single biggest driver of the prognosis for stomach cancer. According to SEER, when the cancer is found early and confined to the stomach, five-year survival is around 78%; once it has spread to nearby lymph nodes that drops to about 39%, and once it has reached distant organs it falls to around 8%. This is a key reason why prompt evaluation of persistent stomach symptoms matters.

What factors offer the best stomach cancer outlook?

The most favorable outlook is generally associated with cancer caught at a localized stage, when it can be fully removed with surgery. Lower tumor grade, a location lower in the stomach rather than near the esophagus, good overall health, and a strong response to initial treatment are also linked to better outcomes. For advanced disease, biomarker testing can identify patients who may benefit from targeted therapy or immunotherapy.

Sources

• National Cancer Institute – Stomach Cancer — Cancer Stat Facts (SEER Program)
• National Cancer Institute – Stomach Cancer Survival Rates and Prognosis
• National Cancer Institute – Stomach Cancer Treatment (PDQ®)–Patient Version
• National Cancer Institute – Stomach Cancer Treatment (PDQ®)–Health Professional Version